预约演示

Teijin and Axcelead sign deal for drug discovery research JV

2023-02-22

交易

并购引进/卖出

The new company will support drug discovery research. Credit: Diane Serik / Unsplash.

Japanese firm Teijin has announced its basic agreement on a capital and business alliance with Axcelead to establish a drug discovery research joint venture (JV) company.

The new companTeijin mainly use Teijin Group’s core healthcare company, Teijin Pharma’s drug diAxceleadresearch capabilities, facilities, personnel, technologies, and equipment.

Its name, ownership ratio and otTeijin Groupare yet to be decided.Teijin Pharma

The two companies aim to conclude a final agreement within the fiscal year ending in March next year and then set up a new company shortly.

In addition to supporting drug discovery research, the new company will investigate and acquire candidate compounds for new drugs.

This new company is expected to increase drug discovery support services globally using Teijin and Axcelead’s combined strengths in drug-discovery knowledge, technology, and assets.

Teijin and Teijin Pharma are looking to innovate and boost drug discovery research throuTeijinir alAxceleador the early launch of drugs for high medical requirements.

This basic Teijin Pharmaalso claimed to accord with the concept of co-creating drug discovery platforms of Axcelead.

Axcelead owns a group of companies that develop a healthcare platform for drug discovery.

Axcelead DDP is claimed to be the first integrated drug discovery solution provider in Japan.

It operates as the core company of the Axcelead group that took over Takeda Pharmaceutical Company’s drug discovery platform business in 2017.

Axcelead DDP is claimed to offer ‘one-sAxcelead groupal drug discoverTakeda Pharmaceutical Companyrom drug-target discovery to optimisation of drug candidate compounds and approaches for linking to clinical development.

机构